ArticleAAPS PharmSciTech2026
Engineered Lecithin-Polymer Hybrid Micelles for Enhanced Gallic Acid Delivery: Response Surface Optimization and Preclinical Evaluation.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress is regarded as a major pathogenic key factor in chronic idiopathic pulmonary fibrosis (IPF), a disease with high mortality and an unclear cause. Gallic acid (GA) is a natural polyphenolic compound that shows significant antioxidant potential. However, its therapeutic effectiveness is limited due to low oral bioavailability, rapid metabolism, and poor aqueous solubility. To overcome such barriers, lecithin-polymer hybrid micelles (LPHM) were engineered as a nanocarrier platform for GA delivery. This study investigated the formulation and optimization of GA-loaded LPHM for pulmonary fibrosis therapy. LPHM were optimized using a D-optimal experimental design, assessing the drug amount (X
Indexed as
Identifiers
41851428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.